Why the study?
Expanding the understanding of metabolic mechanisms underlying PAH may strengthen the development of new therapeutics.
This review highlights the role of metabolic abnormalities in pulmonary arterial hypertension and suggests that targeting these pathways could lead to new therapeutics.
Answers are grounded in this paper and cite their sources.
May inform metabolic-targeted PAH research; leaves open whether such therapies will improve clinical outcomes.
The main characteristic of arterial hypertension (PAH) is the gradual increase in pulmonary artery pressure and impaired vascular growth regulation. Increasingly, animal models of PAH and blood samples from patients with PAH and lung cells from patients with PAH have been found to have metabolic abnormalities. Because of this, changes in metabolism and biological functions are deemed to be common in PAHs. From the perspective of metabolomics, this review introduces metabolic research and possible treatments for pulmonary hypertension. Developing new therapeutics for treating patients can be strengthened by expanding our understanding of the metabolic mechanisms underlying PAH.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: